CLEVELAND & SAN DIEGO -- (EINPresswire.com) -- A multinational breast cancer study has revealed surprising insights into an aggressive cancer phenotype driven by tumor fibrosis—a phenomenon known as mechanical conditioning—which affects nearly half of all breast tumors. The unexpected discovery emboldens drug repositioning and label expansion strategies for second-generation antifibrotics under development at leading pharma companies.
The publication marks the culmination of a multi-year collaboration between MeCo Diagnostics and several prominent research institutes, including Cleveland Clinic and University Hospital Zurich, ranked globally by Newsweek as #2 and #10, respectively, in World’s Best Hospitals 2025. Additional support was provided by the University of Arizona Cancer Center and the USC Norris Comprehensive Cancer Center.
The report, "Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells," appears in the journal Cancers. The study was led by senior author Dr. Julie E. Lang, Chief of Breast Surgery at Cleveland Clinic. It demonstrates that a readout of mechanical conditioning intensifies throughout cancer progression, challenging conventional understanding of the phenomenon.
The study was enabled by the MeCo ScoreTM, a first-in-class biomarker that quantifies mechanical conditioning. The emergent biomarker now boasts three clinical successes; earlier studies demonstrated that High MeCo Scores predicted poor survival in patients, unless they received antifibrotic therapy, which dramatically reduced their risk of recurrence. Given that ~50% of breast tumors are classified as High MeCo Score, the three studies collectively suggest a profound opportunity to improve long-term survival for patients with high-risk breast cancer.
Researchers analyzed patient-matched tumor samples—comparing solid vs. liquid biopsies—from patients with either early- or late-stage disease, thereby producing the first comprehensive analysis of a mechanical conditioning throughout disease progression: MeCo Scores were significantly higher in circulating tumor cells (CTCs) compared to matched primary tumors in stage II-III patients (p = 0.026); and MeCo Scores were significantly higher in distant metastatic tumor sites compared to matched CTCs in stage IV patients (p = 0.0004). This striking pattern also provides compelling support for the fascinating theory of mechanical memory in cancer biology.
“These findings help explain why targeted antifibrotic therapy was remarkably effective for High MeCo Score patients in our landmark Phase 2 study published last year,” explained Dr. Adam Watson, CEO of MeCo Diagnostics and lead inventor of its technology.
The MeCo ScoreTM was specifically designed to be drug-agnostic, pathway-agnostic, and even mechanism-of-action-agnostic, thus maximizing its forward compatibility as a companion diagnostic test for antifibrotic therapies, with broad potential across oncology. Breast cancer alone represents a ~6X larger market than idiopathic pulmonary fibrosis (IPF), the proposed first indication for many antifibrotic drug candidates.
---
About MeCo Diagnostics:
MeCo Diagnostics Holdings, Inc. is a seed-stage medtech company based in San Diego, CA, commercializing first-in-class biomarker tests to match cancer patients with antifibrotic therapy. https://mecodiagnostics.com/
Media Contact:
Keith Grevenitz (keith@mecodiagnostics.com)
MeCo Diagnostics Holdings, Inc.
9191 Towne Centre Drive Ste 150
San Diego, CA 92122